Axitinib

For research use only.

Licensed by Pfizer Catalog No.S1005 Synonyms: AG 013736

92 publications

Axitinib Chemical Structure

CAS No. 319460-85-0

Axitinib (AG 013736) is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 79 In stock
USD 70 In stock
USD 120 In stock
USD 217 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Axitinib has been cited by 92 publications

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Axitinib (AG 013736) is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.
Features Superior as second-line therapy relative to sorafenib (current standard-of-care).
Targets
VEGFR1/FLT1 [1]
(Porcine aorta endothelial cells)
VEGFR2/Flk1 [1]
(Porcine aorta endothelial cells)
VEGFR2/KDR [1]
(Porcine aorta endothelial cells)
VEGFR3 [1]
(Porcine aorta endothelial cells)
PDGFRβ [1]
(Porcine aorta endothelial cells)
0.1 nM 0.18 nM 0.2 nM 0.1 nM-0.3 nM 1.6 nM
In vitro

Axitinib could block the cellular autophosphorylation of VEGFR and VEGF-mediated endothelial cell viability, tube formation, and downstream signaling. Axitinib inhibits the proliferation of variable cell lines with IC50 of >10,000 nM (IGR-N91), 849 nM (IGR-NB8), 274 nM (SH-SY5Y) and 573 nM (non-VEGF stimulated HUVEC). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell NITP[5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEO0NIdKSzVyPUCuNFAxODVzMzFOwG0> MYrTRW5ITVJ?
NCI-H1703 M1SybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwMECwPVAzKM7:TR?= MmDHV2FPT0WU
KASUMI-1 NXzIc2pTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\tUIdKSzVyPUCuNFA3QDJizszN MUTTRW5ITVJ?
CGTH-W-1 NIm4WI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwMEC3NlIh|ryP Mn2xV2FPT0WU
A204 M1PhZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmL4TWM2OD1yLkCwPVkzKM7:TR?= MYjTRW5ITVJ?
HOP-62 M1H1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH25NpNKSzVyPUCuNVA5OzZizszN MXfTRW5ITVJ?
H-EMC-SS MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PGbWlEPTB;MD6xNVAxPSEQvF2= NW\yXY1lW0GQR1XS
KU812 MkjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\SVmlEPTB;MD6xOlU4PyEQvF2= Mo\QV2FPT0WU
EM-2 NGD4XGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwMU[4NVYh|ryP M{\FVXNCVkeHUh?=
LAMA-84 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\4PJk5UUN3ME2wMlE4PjZ3IN88US=> NVPTSmFNW0GQR1XS
JAR MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7TTWM2OD1yLkKzPVg6KM7:TR?= Ml[xV2FPT0WU
G-361 M4PxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXUeZpKSzVyPUCuN|I{OjVizszN M4fzXHNCVkeHUh?=
KG-1 M{LP[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwM{e2OFIh|ryP M4rMZnNCVkeHUh?=
BV-173 NW\hVnpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrVXlBKSzVyPUCuN|k{OiEQvF2= Mn7DV2FPT0WU
K5 M3jocGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLvT5ZFUUN3ME2wMlQzOTJ5IN88US=> NYrRNlFSW0GQR1XS
MEG-01 MlrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTBwNEKzOlEh|ryP NEnJ[WJUSU6JRWK=
MFM-223 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3hd2VKSzVyPUCuOFQ4PzZizszN NIq2UWlUSU6JRWK=
BE-13 M3nn[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljvTWM2OD1yLkWxNFA5KM7:TR?= NX3qXGhlW0GQR1XS
NEC8 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXz3cG1GUUN3ME2wMlczOTF|IN88US=> M1XMUXNCVkeHUh?=
SW756 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTBwOUm4OFYh|ryP NWWxeY04W0GQR1XS
A2780 NIHaSmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTFwMEGxOFYh|ryP M2XqU3NCVkeHUh?=
NB14 M3Gwdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTFwMEG4NFEh|ryP M2TC[nNCVkeHUh?=
H4 Ml7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXHO2FtUUN3ME2xMlA3PDJ{IN88US=> NGXObVFUSU6JRWK=
SK-OV-3 NETLUHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmm0TWM2OD1zLkC2OlM{KM7:TR?= NVTESXlsW0GQR1XS
AN3-CA MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTFwMEizPFkh|ryP M4G5UHNCVkeHUh?=
A427 NE\pNpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rtSWlEPTB;MT6xNFM5OSEQvF2= NWn4c5JiW0GQR1XS
ES7 NXn1R|R5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fue2lEPTB;MT6xNVM{PCEQvF2= NX;6bm1ZW0GQR1XS
AGS MoKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vnOGlEPTB;MT6xNVM6PSEQvF2= Mk\hV2FPT0WU
G-402 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkC3TWM2OD1zLkG0Olk1KM7:TR?= Mme2V2FPT0WU
ES5 NIL1UWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TuWGlEPTB;MT6xO|I1QCEQvF2= NIPFbJlUSU6JRWK=
DEL M2PtXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTFwMkW0OVch|ryP NUL3cZFIW0GQR1XS
NB10 M3vWcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHRTJlKSzVyPUGuN|I2PTdizszN M16xSXNCVkeHUh?=
NCI-H1581 NHfqN|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHaZ3lFUUN3ME2xMlM6ODR{IN88US=> MUjTRW5ITVJ?
D-566MG NV72WW1FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fMU2lEPTB;MT60NFY5OyEQvF2= NXniXVV[W0GQR1XS
LXF-289 NH7IRoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnaeoFEUUN3ME2xMlQ{QTl4IN88US=> MnrKV2FPT0WU
BT-549 NYDzU4ZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\MSYE1UUN3ME2xMlU3QTB7IN88US=> NGXqRWRUSU6JRWK=
NKM-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\lNVJDUUN3ME2xMlYxPTV4IN88US=> NUm0WoZoW0GQR1XS
SW780 NVzqTGhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrrSW1KSzVyPUGuOlUyPThizszN MkD4V2FPT0WU
NCI-H292 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTFwNk[zPFMh|ryP M1y4dnNCVkeHUh?=
HMV-II MnrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPUTHdLUUN3ME2xMlcxPDh6IN88US=> MlnWV2FPT0WU
ALL-PO MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2T6VmlEPTB;MT64NFAyPSEQvF2= MXLTRW5ITVJ?
UACC-257 NUP1WW9{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTFwOEKxOlMh|ryP MmOyV2FPT0WU
PA-1 NEXXeWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDoTWM2OD1zLkiyO|I2KM7:TR?= NFnpe3pUSU6JRWK=
HD-MY-Z M1\jfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTFwOE[yPFEh|ryP MU\TRW5ITVJ?
HSC-4 NXSwVoFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTFwOUO4N|kh|ryP NXT4Z3ZNW0GQR1XS
GCT Mm\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPZ[5JKSzVyPUKuNFA6OTZizszN NVPHNFJsW0GQR1XS
RT-112 NXK5c5AxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTJwMUO0NlQh|ryP NGf2UYhUSU6JRWK=
A172 M2Pndmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XVZmlEPTB;Mj6xN|YxPiEQvF2= M13renNCVkeHUh?=
HCE-T NIH0V5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1W1bWlEPTB;Mj6yNFU6QCEQvF2= MmHiV2FPT0WU
YH-13 NYXpVXVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13ONGlEPTB;Mj6yNVY4OSEQvF2= M1G2T3NCVkeHUh?=
DK-MG NVj5bmhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3HTWM2OD1{LkKzPFM1KM7:TR?= MoSyV2FPT0WU
ACN MoP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfwdFN3UUN3ME2yMlI{QDd3IN88US=> M4rJ[XNCVkeHUh?=
VA-ES-BJ NWDFc5BCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJwMkS5OVch|ryP NIPj[XhUSU6JRWK=
L-363 NFHabGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\OTWM2OD1{LkK4NFYyKM7:TR?= MYDTRW5ITVJ?
HuH-7 NHzhNnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHBUIdKSzVyPUKuOFIyPjVizszN NVK5PZBOW0GQR1XS
A4-Fuk M1Ht[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTJwNEexOlgh|ryP MV3TRW5ITVJ?
T-24 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvUTWM2OD1{LkS4NFM4KM7:TR?= NWT0NnpGW0GQR1XS
GOTO NWPVRZZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTJwNUOwNVMh|ryP M3T4ZXNCVkeHUh?=
MV-4-11 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvGeZNKSzVyPUKuOVkyPjlizszN NXfwVYxEW0GQR1XS
DMS-114 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;wTWM2OD1{Lk[2N|Q2KM7:TR?= M3rjTXNCVkeHUh?=
MHH-NB-11 MojLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTJwN{CyPVkh|ryP MnO4V2FPT0WU
CHP-212 MnOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlGwTWM2OD1{LkiyNFkyKM7:TR?= NGXNTWpUSU6JRWK=
DMS-273 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDlVYNKSzVyPUKuPVAzODdizszN MXjTRW5ITVJ?
SF295 NVLsS5lVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTNwMEK1PVch|ryP M3P6cnNCVkeHUh?=
NCI-H1563 NWPKUpJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTjTWM2OD1|LkG1NFA2KM7:TR?= M1iwTXNCVkeHUh?=
NCI-H446 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknUTWM2OD1|LkKyPFA2KM7:TR?= MkXOV2FPT0WU
HCC1806 MnLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjwTIE1UUN3ME2zMlI4PjV5IN88US=> M13EVXNCVkeHUh?=
SF126 NYfBdGY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\tWohKSzVyPUOuN|AxOTdizszN NH3FOohUSU6JRWK=
SW982 NGG3RWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLmTWM2OD1|LkOzPFc2KM7:TR?= Mn\YV2FPT0WU
ES8 M2rZRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nCbmlEPTB;Mz6zOFk6QSEQvF2= MkPoV2FPT0WU
SCC-4 Mmf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorGTWM2OD1|LkWwN|k3KM7:TR?= MWXTRW5ITVJ?
RPMI-8226 NXT4fY1wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTNwNkK2NVYh|ryP MlzjV2FPT0WU
EW-11 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfORnpKSzVyPUOuOlMxOjJizszN MYTTRW5ITVJ?
COR-L105 M{\UOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PGfmlEPTB;Mz62N|M{PCEQvF2= MWfTRW5ITVJ?
ES1 MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPCd3Z[UUN3ME2zMlg{ODl2IN88US=> M3LkOXNCVkeHUh?=
KMOE-2 M2PRW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTNwOUG4NFgh|ryP NXHZeY53W0GQR1XS
ABC-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3[5e2lEPTB;Mz65N|kyOSEQvF2= M{XreHNCVkeHUh?=
NCI-H526 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3zTWM2OD1|Lkm5NVI3KM7:TR?= M3XRU3NCVkeHUh?=
HCC1395 MlnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDXNFBzUUN3ME2zMlk6PDh2IN88US=> NXHFeI14W0GQR1XS
DU-145 M1;qbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTRwMUK4NlUh|ryP M{P4S3NCVkeHUh?=
JEG-3 Mmj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjlNJhMUUN3ME20MlE2QTF4IN88US=> M2foTHNCVkeHUh?=
HCC1187 MlvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jkN2lEPTB;ND6yNVU6PyEQvF2= MWTTRW5ITVJ?
LC-2-ad MorxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPZTWM2OD12LkKyNVc4KM7:TR?= NUS5VHFEW0GQR1XS
ONS-76 M1vZbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTRwMkSxPVIh|ryP NVi3S3VDW0GQR1XS
CAL-27 MkO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4izbGlEPTB;ND6yOFM1PCEQvF2= MmLuV2FPT0WU
8-MG-BA NUnnZYhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTRwMk[2OVgh|ryP Ml3TV2FPT0WU
HGC-27 Ml:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfYTWM2OD12LkK5OlYh|ryP MXnTRW5ITVJ?
Hs-578-T NHXPfWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfrW|BnUUN3ME20MlMyPDZ6IN88US=> NUPDR4pPW0GQR1XS
EW-1 Mn3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDEdYxPUUN3ME20MlU{ODF2IN88US=> MVPTRW5ITVJ?
SW1573 NFK3eJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVroZVdHUUN3ME20MlU2OTZ|IN88US=> M2\QT3NCVkeHUh?=
SNU-423 NV;0eJBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTRwNkC3PUDPxE1? NY\6e21UW0GQR1XS
HOS M1\NN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jyRmlEPTB;ND62PVc4KM7:TR?= NUH5eWQ4W0GQR1XS
LB1047-RCC MoHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{S5d2lEPTB;ND64NVQyQCEQvF2= MlL0V2FPT0WU
ChaGo-K-1 NXXLOZRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofGTWM2OD12Lki5NFQ5KM7:TR?= MWHTRW5ITVJ?
A3-KAW NXTqXYx3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTRwOUezOVIh|ryP MUXTRW5ITVJ?
CAS-1 NHTMd2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrnTWM2OD12Lkm5PVA5KM7:TR?= MlHkV2FPT0WU
NBsusSR M{LUdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTVwMEO1NVQh|ryP Mn\PV2FPT0WU
KM12 M{XEN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfjfIRKSzVyPUWuNlk5OjdizszN MVvTRW5ITVJ?
NCI-H1155 NWjkUnhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTVwM{ixPFUh|ryP MUTTRW5ITVJ?
EFM-19 NGPHRnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF76WpZKSzVyPUWuOFE4OzdizszN MUHTRW5ITVJ?
D-392MG MnTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3O4dmlEPTB;NT61O|g1QSEQvF2= NX;WVmloW0GQR1XS
JVM-3 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorkTWM2OD13LkeyN|I2KM7:TR?= MX;TRW5ITVJ?
EW-16 MlHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTVwN{W1PFMh|ryP MYXTRW5ITVJ?
KARPAS-45 NXn5PGR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTVwOESzNlUh|ryP NWr4UoNYW0GQR1XS
NCI-H28 NHvVXpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\XOlRKSzVyPUWuPFc6OThizszN MnmzV2FPT0WU
COLO-829 NWDKZ5BlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDaTWM2OD13LkmxOVA1KM7:TR?= MnXWV2FPT0WU
KM-H2 NXr3cFg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTVwOUKzPVUh|ryP MXHTRW5ITVJ?
NCI-H82 MnT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTVwOUK3O|Eh|ryP NInzZmhUSU6JRWK=
OAW-42 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFL3dVhKSzVyPUWuPVg5OjFizszN MWnTRW5ITVJ?
A704 MmL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rWTWlEPTB;Nj6xNFU4PCEQvF2= NIrSXmlUSU6JRWK=
NCI-H1048 NEDCbWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MneyTWM2OD14LkGwOVk6KM7:TR?= MV3TRW5ITVJ?
LOXIMVI MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjGTWM2OD14LkGxNlQ5KM7:TR?= MnHCV2FPT0WU
MKN45 NHv2cplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTZwMk[wNVYh|ryP MmLIV2FPT0WU
D-502MG MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7FOXBqUUN3ME22MlI5QDV5IN88US=> M3rUNnNCVkeHUh?=
HUTU-80 NEG4TVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLxZphKSzVyPU[uOFE3QDhizszN NFfhc3BUSU6JRWK=
S-117 MmLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHnTWM2OD14LkWwNlY4KM7:TR?= NFjSPFFUSU6JRWK=
HCC1569 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVz4N2lRUUN3ME22MlU{PzN5IN88US=> MVrTRW5ITVJ?
J-RT3-T3-5 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTZwNUS1O|Ih|ryP MWPTRW5ITVJ?
OC-314 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{m3c2lEPTB;Nj65NVE2QSEQvF2= NH;aVXhUSU6JRWK=
SNU-449 NVrtVXdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXNbnJbUUN3ME23MlAyODd{IN88US=> MoXQV2FPT0WU
NCI-H720 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonaTWM2OD15LkG5N|Q2KM7:TR?= NXXySlZZW0GQR1XS
KP-N-YS M3GweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnRdlNKSzVyPUeuNlA4OiEQvF2= NIGwO25USU6JRWK=
IGROV-1 NHLOR5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTdwM{KzPFYh|ryP MmPRV2FPT0WU
SK-PN-DW MlPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXX0cGpMUUN3ME23MlQ5OTVizszN MkPIV2FPT0WU
HCC1419 MoHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVz0TndGUUN3ME23MlU{KM7:TR?= MVfTRW5ITVJ?
HAL-01 NYD4[XRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37JdGlEPTB;Nz62NFY1PCEQvF2= NEnybGhUSU6JRWK=
HCC2998 M4rZSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTdwNkC3OFMh|ryP NVLSNWxtW0GQR1XS
SK-N-FI NUTOWoVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;pOplOUUN3ME23MlY{ODN|IN88US=> NUm5RZhJW0GQR1XS
GI-ME-N M3Lvd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXP2[VNrUUN3ME23MlY1QTN2IN88US=> NHOyTZhUSU6JRWK=
SW1088 NFvVbotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXaV|BKSzVyPUeuOlU5OjZizszN MmHRV2FPT0WU
IA-LM M1;OZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTdwNki2NVMh|ryP MWHTRW5ITVJ?
SK-NEP-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3nTWM2OD15Lk[5OlEh|ryP M{C4N3NCVkeHUh?=
MDA-MB-415 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXf0bVFZUUN3ME23Mlg6OTh4IN88US=> NV;uRoI2W0GQR1XS
COLO-800 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELYZ3FKSzVyPUeuPVQ1QTJizszN NG[0doVUSU6JRWK=
NCI-H2228 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrQTWM2OD16LkG1O|g{KM7:TR?= NGnhZoNUSU6JRWK=
D-423MG NYrKXlF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRThwMkG3NkDPxE1? MUPTRW5ITVJ?
TE-1 NHjKUIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[1VXVKSzVyPUiuOFQ{OTZizszN NFzWfo5USU6JRWK=
NOS-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPlVXVoUUN3ME24MlUyPTN2IN88US=> NX7DTnVMW0GQR1XS
8505C NF;oNXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfLVFZDUUN3ME24MlY1QDJ2IN88US=> M1;aV3NCVkeHUh?=
HEC-1 NHK3[lVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWH3XnYyUUN3ME24Mlc5PDN7IN88US=> MVXTRW5ITVJ?
TE-11 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\tTWM2OD16Lkm5OVUyKM7:TR?= M2XscXNCVkeHUh?=
CTB-1 M4PRZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEj5cXJKSzVyPUmuNFE1OzNizszN NH34SoxUSU6JRWK=
TGBC11TKB MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLGTmZ1UUN3ME25MlAzOjRzIN88US=> MYnTRW5ITVJ?
NB17 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXzVGZIUUN3ME25MlE5QDdizszN MkPHV2FPT0WU
Becker MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPJOmNXUUN3ME25MlQyQTR2IN88US=> NUHhWmFzW0GQR1XS
SN12C M2TSPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUK0fJI5UUN3ME25MlQ2OjN2IN88US=> MUXTRW5ITVJ?
COLO-320-HSR NWL3cnhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWP5OpNGUUN3ME25MlYxOjN5IN88US=> MVTTRW5ITVJ?
D-283MED NGXlbGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrFPY03UUN3ME25MlY{ODd{IN88US=> M2nG[nNCVkeHUh?=
D-263MG NFXjXFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TxSGlEPTB;OT64N|M5PCEQvF2= NV;yZnBQW0GQR1XS
MEL-JUSO M2nzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3PTZZlUUN3ME25MlkxOTJ5IN88US=> M3XVNXNCVkeHUh?=
T98G M4rSPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTlwOUCyNFMh|ryP MYXTRW5ITVJ?
HLE NFfPV5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2X1N2lEPTB;OT65NFkxQSEQvF2= NYjn[nBlW0GQR1XS
Ca9-22 Mke2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmT1TWM2OD1zMD6wOlY2KM7:TR?= Ml7NV2FPT0WU
OS-RC-2 MkLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnoZW1KSzVyPUGwMlExPDVizszN MUjTRW5ITVJ?
T47D M2T5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTFyLkG1OUDPxE1? NYnOZ4cyW0GQR1XS
GI-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPhc4d3UUN3ME2xNE4{PTN|IN88US=> NYT1NFZoW0GQR1XS
NUGC-3 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnj0TWM2OD1zMD60OFAzKM7:TR?= M4SzWnNCVkeHUh?=
MDA-MB-361 NH3TfGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTFyLkS0N|Ih|ryP M3qxdnNCVkeHUh?=
SCC-15 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELE[mlKSzVyPUGwMlQ4OThizszN MYXTRW5ITVJ?
KS-1 MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTFyLk[zNFEh|ryP Ml\4V2FPT0WU
CAL-12T NIjiOI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHG3PHhKSzVyPUGwMlY{PjFizszN MYHTRW5ITVJ?
OVCAR-4 MmrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;nXGVYUUN3ME2xNE44ODZ6IN88US=> M{\yUnNCVkeHUh?=
HuP-T4 NEnqVHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTFzLkCzNlgh|ryP NGPDWnBUSU6JRWK=
NCI-H358 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLINllCUUN3ME2xNU4zPjV5IN88US=> M2PlcHNCVkeHUh?=
HO-1-N-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTFzLkOzPVgh|ryP MnHZV2FPT0WU
NH-12 Mm\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mle2TWM2OD1zMT61N|c5KM7:TR?= M4D5bnNCVkeHUh?=
MOLT-4 NXPSUW5wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTFzLkW5PFUh|ryP M2PvVXNCVkeHUh?=
K-562 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHudmZYUUN3ME2xNU44OjR6IN88US=> MkLiV2FPT0WU
ES6 NYPOR|VyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTFzLki1PFEh|ryP MoS1V2FPT0WU
RO82-W-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHaSplKSzVyPUGxMlkxPjRizszN M33Zd3NCVkeHUh?=
Ramos-2G6-4C10 M1rxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fNR2lEPTB;MUGuPVMzKM7:TR?= NVjCNGRKW0GQR1XS
23132-87 NHrqW2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTF{LkC4NlEh|ryP M{ewOXNCVkeHUh?=
A549 NG[wXXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\rTWM2OD1zMj6zNlg2KM7:TR?= MV3TRW5ITVJ?
NCI-H23 M{TxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTF{LkWwNlYh|ryP NULkblh1W0GQR1XS
H9 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTF{LkW1O|ch|ryP Mn3vV2FPT0WU
LB771-HNC NF;D[|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfJU|l5UUN3ME2xNk44PjVizszN M4K1O3NCVkeHUh?=
QIMR-WIL NHv4bmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTvTWM2OD1zMj64NlU5KM7:TR?= NU\1O2x5W0GQR1XS
HSC-3 NWftSpduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1v4cGlEPTB;MUKuPVI4PiEQvF2= MnnoV2FPT0WU
PFSK-1 NVTmd3hGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvU[41KSzVyPUGyMlk2ODdizszN NHTtWHhUSU6JRWK=
ETK-1 Mn3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHGTWM2OD1zMz6wO|c6KM7:TR?= NVTkV|hzW0GQR1XS
SW1710 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTF|LkO2OFEh|ryP MUDTRW5ITVJ?
COLO-684 NVXUcFk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTF|LkS1OFEh|ryP NFnRcWtUSU6JRWK=
RPMI-7951 MkHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTF|LkWxN|Yh|ryP NEnVbmhUSU6JRWK=
A101D NF;v[mhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;6TWM2OD1zMz61N|Q6KM7:TR?= M1fQR3NCVkeHUh?=
KE-37 MoXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITxSW9KSzVyPUGzMlU5QDdizszN NXS3d4VxW0GQR1XS
SiHa MmnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTF|LkizOFYh|ryP MV\TRW5ITVJ?
NCI-H226 NILVV2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4W1OWlEPTB;MUOuPFgxQCEQvF2= NU[4NHJ3W0GQR1XS
DB MlL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTF|Lkm5Nlgh|ryP NH\Hc4ZUSU6JRWK=
HT-1197 NVPVfWl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;4WIFbUUN3ME2xOE4xQDB7IN88US=> MmrPV2FPT0WU
SBC-5 MkHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDJOJpKSzVyPUG0MlE{PjJizszN MWDTRW5ITVJ?
VMRC-RCZ M3q0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7aTWM2OD1zND61O|c1KM7:TR?= MUnTRW5ITVJ?
697 MkTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTF2Lk[yO{DPxE1? M17GXXNCVkeHUh?=
OMC-1 NFnFUYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTF2Lke4PFgh|ryP NUnkb45KW0GQR1XS
SKG-IIIa MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTF2LkiwNFEh|ryP NHHaVY9USU6JRWK=
DOK MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XEZmlEPTB;MUSuPVk{OyEQvF2= MX\TRW5ITVJ?
NCI-H2029 M3fVdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnsToEzUUN3ME2xOU4{PjB{IN88US=> NH\6bVFUSU6JRWK=
NCI-H2009 NX:1OJNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmj1TWM2OD1zNT61NFk2KM7:TR?= M{\ITnNCVkeHUh?=
LK-2 NELQc5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkf0TWM2OD1zNT62OFQ6KM7:TR?= NXrYXVZTW0GQR1XS
NCI-H661 NV\5TGhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzkTWM2OD1zNT65NFc2KM7:TR?= MUXTRW5ITVJ?
GT3TKB NHLMeJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTF4LkC2O|Yh|ryP Mn7zV2FPT0WU
GP5d Ml21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTF4LkO0NkDPxE1? MWnTRW5ITVJ?
SK-MEL-2 MofpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\hTWM2OD1zNj60OFg2KM7:TR?= MYHTRW5ITVJ?
SK-UT-1 NV3sOI1iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLCNFNpUUN3ME2xOk42PjVizszN NFjYeHZUSU6JRWK=
NB7 NVi4c4JlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHv0OJFKSzVyPUG2MlY6PzFizszN M3nMV3NCVkeHUh?=
NCI-H460 M37DPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zkR2lEPTB;MU[uO|MzPiEQvF2= MmTWV2FPT0WU
8305C MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTF4Lke4O|ch|ryP Mn;JV2FPT0WU
CaR-1 NYP6WpBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonYTWM2OD1zNj64NVEyKM7:TR?= MljHV2FPT0WU
D-247MG M3zWSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTF4Lki2NlUh|ryP NIKyZohUSU6JRWK=
LoVo NEfOUWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jUTmlEPTB;MU[uPVQ5QCEQvF2= MnvXV2FPT0WU
NCI-H2405 NY\yUItlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTF5LkG5NFgh|ryP M3naXHNCVkeHUh?=
AU565 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnKOWFzUUN3ME2xO{4zOjVizszN NXrVcHp6W0GQR1XS
OCI-AML2 Mo\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTF5LkWzNVch|ryP NIfOPGpUSU6JRWK=
22RV1 MnvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTF5LkW4PFQh|ryP NEm4fmRUSU6JRWK=
HT-144 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoH3TWM2OD1zNz62OVk5KM7:TR?= MVvTRW5ITVJ?
HuO9 MkfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDI[pBRUUN3ME2xO{44ODNzIN88US=> MWnTRW5ITVJ?
Daoy M{noT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1L0XWlEPTB;MUeuO|E5PCEQvF2= M3j1[nNCVkeHUh?=
SJRH30 M37Zbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TQUWlEPTB;MUeuPFQ5QSEQvF2= MmnxV2FPT0WU
CHL-1 M1TybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\kVYo6UUN3ME2xO{46OjR7IN88US=> NU\kUlZGW0GQR1XS
J82 NULCT4w5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTkTWM2OD1zNz65OlM2KM7:TR?= MnniV2FPT0WU
COR-L23 M3;s[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTF6LkCwNVEh|ryP M{eyb3NCVkeHUh?=
SNU-C2B M1z3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLTTWM2OD1zOD6yNlc3KM7:TR?= MmDaV2FPT0WU
NCI-H1770 M1WyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fncmlEPTB;MUiuOFYyPSEQvF2= M3\FfHNCVkeHUh?=
MHH-PREB-1 NWjrcpA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4S1TmlEPTB;MUiuOVY6PyEQvF2= NU\icJU{W0GQR1XS
ES3 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3M[JBzUUN3ME2xPE42QDh|IN88US=> MWTTRW5ITVJ?
MDA-MB-231 NUjZeWFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTF6Lk[1NFIh|ryP MWXTRW5ITVJ?
MN-60 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXIZodnUUN3ME2xPU4xPTl{IN88US=> M{PhUHNCVkeHUh?=
EPLC-272H MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1r5[mlEPTB;MUmuN|cxQCEQvF2= M1PN[nNCVkeHUh?=
SW948 MojPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEC1U5FKSzVyPUG5MlM6OzRizszN NETMNW5USU6JRWK=
MOLT-13 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTF7LkS1OFYh|ryP NH7ROZNUSU6JRWK=
HL-60 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnS5TWM2OD1{MD6yNVQyKM7:TR?= NYLENXV6W0GQR1XS
CP50-MEL-B MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWq3fZhsUUN3ME2yNE41PzR6IN88US=> NYOzZXNYW0GQR1XS
NTERA-S-cl-D1 M2jGNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7CTWM2OD1{MD60PVc5KM7:TR?= MmLWV2FPT0WU
KINGS-1 Ml7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jtVmlEPTB;MkCuO|k3PyEQvF2= NV7PO4VZW0GQR1XS
DOHH-2 MnfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTJyLkmwOkDPxE1? M{GzeHNCVkeHUh?=
BB65-RCC M4ToOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjaVId1UUN3ME2yNE46Ojh3IN88US=> MoXFV2FPT0WU
NB12 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnH2TWM2OD1{MT6wN|k1KM7:TR?= NX;jdXNDW0GQR1XS
KY821 Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH:4U|FKSzVyPUKxMlU5OiEQvF2= MnrNV2FPT0WU
PSN1 M1;wW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\MTWM2OD1{MT62OFU{KM7:TR?= M2DHVHNCVkeHUh?=
EGI-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PvSWlEPTB;MkGuO|Q2PCEQvF2= MkXTV2FPT0WU
CTV-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\0ZYhKSzVyPUKyMlMxOzFizszN MWDTRW5ITVJ?
TI-73 Mn;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTJ{LkO0PVgh|ryP NXOwPJZtW0GQR1XS
LCLC-103H M{DH[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFP2N2VKSzVyPUKyMlQ4PTJizszN NIm5OnNUSU6JRWK=
D-542MG M4CyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonjTWM2OD1{Mj61OVU5KM7:TR?= NFLYdmtUSU6JRWK=
ATN-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTJ{Lk[0N|kh|ryP MX3TRW5ITVJ?
SK-MEL-1 NYrNOnhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTJ{LkizOlgh|ryP NXXFc2lxW0GQR1XS
HDLM-2 M1jWSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTJ|LkG0O|gh|ryP Ml:4V2FPT0WU
UM-UC-3 M2nDUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnxVlI4UUN3ME2yN{4yQTR2IN88US=> M17ocXNCVkeHUh?=
NCI-H1573 Mm\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj6WlVwUUN3ME2yN{41PjhzIN88US=> M1HXUHNCVkeHUh?=
NCI-H520 NXvWXJhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfld3ZCUUN3ME2yN{41QTR6IN88US=> NV23NGp6W0GQR1XS
ESS-1 NGnVSpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTJ|LkiwOVkh|ryP NUjPbI9TW0GQR1XS
COR-L88 Mki0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTJ|Lkm0O|Uh|ryP M3jtd3NCVkeHUh?=
TGBC24TKB NYTtUIY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHH3T4pKSzVyPUK0MlA{OTJizszN NH;YNHVUSU6JRWK=
HCC1937 M3zUOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTJ2LkGg{txO MWPTRW5ITVJ?
RS4-11 MmfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofMTWM2OD1{ND6xOFIh|ryP M3i4fHNCVkeHUh?=
HCC38 M2GxU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\DNmlEPTB;MkSuNlM6PCEQvF2= NETGeFdUSU6JRWK=
RPMI-2650 NFGyOnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmniTWM2OD1{ND62NVYzKM7:TR?= NUC2fZBLW0GQR1XS
P12-ICHIKAWA M1rmUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTJ2Lk[yOVgh|ryP MVXTRW5ITVJ?
YAPC MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3DTWM2OD1{ND64NlE1KM7:TR?= M4DQZ3NCVkeHUh?=
NB13 M2TMfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvVZYw5UUN3ME2yOU4zPjFzIN88US=> NGW2Z4VUSU6JRWK=
SK-N-AS MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4focWlEPTB;MkWuPFU5PCEQvF2= NGLkPIJUSU6JRWK=
SK-N-DZ MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1u5WWlEPTB;Mk[uNFQ6KM7:TR?= M{fpXnNCVkeHUh?=
LS-411N NWLLNplOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3lXoM3UUN3ME2yOk4zODN6IN88US=> M2rV[nNCVkeHUh?=
NCI-H810 M3SyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrxZ5lOUUN3ME2yOk4{OTF{IN88US=> NWHxWnRmW0GQR1XS
NCI-SNU-1 M4rR[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX[1O2U2UUN3ME2yOk42PDV2IN88US=> MYHTRW5ITVJ?
HH Mm\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnKb5FKSzVyPUK2MlU2OjlizszN NXvFSoxzW0GQR1XS
U-2-OS NHX6[FNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfsRmxzUUN3ME2yOk44Ozh{IN88US=> Mni3V2FPT0WU
SF539 M3PuZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoX0TWM2OD1{Nj64NFE5KM7:TR?= M3TlWXNCVkeHUh?=
NCI-H2052 MlzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{H1NmlEPTB;MkeuNFg3KM7:TR?= NYPrb4FqW0GQR1XS
A673 NEnNU4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPSTWM2OD1{Nz6yNVAzKM7:TR?= M2nrWXNCVkeHUh?=
WM-115 MkLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XSSmlEPTB;MkeuO|c3PyEQvF2= NF3OeVJUSU6JRWK=
SW48 NHe4TG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nMcmlEPTB;MkeuPFAxPSEQvF2= NYnMdJNkW0GQR1XS
NOMO-1 M3SyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTJ5Lki1N|Ih|ryP NHW1eoJUSU6JRWK=
PC-3 Mn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTJ5Lki5OFEh|ryP MYTTRW5ITVJ?
UMC-11 Mom0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvOTWM2OD1{Nz65N|Q{KM7:TR?= M4jVcnNCVkeHUh?=
U-118-MG MkG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrz[|FKSzVyPUK4MlAyOjNizszN MljqV2FPT0WU
NCI-H2452 M1vRfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTJ6LkC4NlIh|ryP NUDCNJpvW0GQR1XS
CAMA-1 M3HIOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTJ6Lki1OlQh|ryP NHPyXHVUSU6JRWK=
MC-IXC NVS0N2RvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fQTmlEPTB;MkmuNlM3PiEQvF2= NULhNFFXW0GQR1XS
ES4 MmX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrOTmJwUUN3ME2yPU4{OTd{IN88US=> M{DpfHNCVkeHUh?=
BHT-101 NFHHXoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrNWG1KSzVyPUK5MlMzOSEQvF2= NUjXW2I6W0GQR1XS
KP-4 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorSTWM2OD1{OT61NVYh|ryP Mk\vV2FPT0WU
CAL-54 MmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTJd45KSzVyPUK5MlU1PDVizszN NHKzV4JUSU6JRWK=
5637 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTJ7Lk[0NlEh|ryP NXjHZpNWW0GQR1XS
MOLT-16 M{fMNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTJ7LkeyOlkh|ryP M1jB[3NCVkeHUh?=
Ca-Ski NVm4UopoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTJ7Lkm0OkDPxE1? NEi5WVdUSU6JRWK=
AsPC-1 NVT6VFR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4m3UGlEPTB;M{CuNFIyOiEQvF2= NX;Md3c4W0GQR1XS
MSTO-211H MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXENnhKSzVyPUOwMlE2KM7:TR?= NHvZPIZUSU6JRWK=
L-428 M4fuTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfPcY1mUUN3ME2zNE41ODVizszN MVrTRW5ITVJ?
SW1463 M4nSUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTXUlNXUUN3ME2zNE42Ozh|IN88US=> MmjNV2FPT0WU
NCI-H1648 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LtZ2lEPTB;M{CuOVU4PCEQvF2= MVjTRW5ITVJ?
CAKI-1 M4Kz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYCzNmJrUUN3ME2zNE44PzB{IN88US=> NVPvTot6W0GQR1XS
YKG-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7NfmpKSzVyPUOxMlAzPjNizszN MXnTRW5ITVJ?
A2058 NU\ubW9{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXqeWVKSzVyPUOxMlEyPjRizszN NVHlWXBwW0GQR1XS
A375 M4fTUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PGWWlEPTB;M{GuNVY6PiEQvF2= MVjTRW5ITVJ?
SNB75 M3K2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLIU4JKSzVyPUOxMlI1OzVizszN MWPTRW5ITVJ?
SK-HEP-1 MmTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XLWWlEPTB;M{GuOFI4OSEQvF2= MVLTRW5ITVJ?
ME-180 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TDeWlEPTB;M{GuOlU1OiEQvF2= MUDTRW5ITVJ?
NCI-H209 MnHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTyWJdJUUN3ME2zNU45OjR5IN88US=> M3rCW3NCVkeHUh?=
HC-1 MlPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3XTWM2OD1|Mj6xOFQ3KM7:TR?= MUfTRW5ITVJ?
LB373-MEL-D MljrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnYXXRiUUN3ME2zNk4yQTdzIN88US=> Mo\1V2FPT0WU
SNU-387 M2X0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLsXI5sUUN3ME2zNk4{OTlzIN88US=> NUjRbHF5W0GQR1XS
C32 MnPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnKTXRuUUN3ME2zNk4{OzV|IN88US=> M3HicnNCVkeHUh?=
EW-13 NHrMOW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LkfWlEPTB;M{KuPVQxQCEQvF2= NFfid|BUSU6JRWK=
BFTC-905 NID2UIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mne5TWM2OD1|Mz61NVM3KM7:TR?= NHvDZXdUSU6JRWK=
NCI-H1299 MlPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVSxW441UUN3ME2zN{42PjJzIN88US=> M3PzTXNCVkeHUh?=
LU-135 MoO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTN|LkiwNUDPxE1? NF30cnZUSU6JRWK=
NCI-H2122 NXm4OWRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlL2TWM2OD1|Mz65PVY3KM7:TR?= M1K0cnNCVkeHUh?=
SK-LMS-1 NES2SXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDLfZlKSzVyPUO0MlQyODdizszN NH\COXVUSU6JRWK=
LNCaP-Clone-FGC Ml\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTtO5BVUUN3ME2zOE45PTF3IN88US=> NH35VlVUSU6JRWK=
NCI-H1092 NVjGbYxFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnWZotxUUN3ME2zOU4zPzR5IN88US=> M{jkb3NCVkeHUh?=
MS-1 NVriUZpGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoT5TWM2OD1|NT6zNFM5KM7:TR?= MnLuV2FPT0WU
KYSE-510 MlHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfjNo5KSzVyPUO1MlUxPDJizszN Mkj1V2FPT0WU
NCI-H1793 NV60NndtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETodFlKSzVyPUO1MlY2PDVizszN M2DSNHNCVkeHUh?=
MIA-PaCa-2 M2jzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXyU3hKSzVyPUO2MlA1QTZizszN MkToV2FPT0WU
EW-22 MojnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDKV4xjUUN3ME2zOk41ODd{IN88US=> MkXzV2FPT0WU
IGR-1 MkXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTwOVRKSzVyPUO2MlgyQDRizszN NFXQO2dUSU6JRWK=
HT-1080 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPaTWM2OD1|Nz6xNlUh|ryP MoTWV2FPT0WU
M14 NUX2UnM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1[4SmlEPTB;M{euNVY1OiEQvF2= M{DpWXNCVkeHUh?=
786-0 M4fCdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jJN2lEPTB;M{euNlc6PCEQvF2= MWHTRW5ITVJ?
MZ2-MEL NXy0U3RrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPjOlUyUUN3ME2zO{41PTBzIN88US=> M1vtSnNCVkeHUh?=
NCI-H510A NVvOSoZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrXS45KSzVyPUO3Mlk1OTJizszN MmLYV2FPT0WU
LAN-6 M{fXSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LnTWlEPTB;M{euPVU5OiEQvF2= NETr[|dUSU6JRWK=
SW620 Ml\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vYVGlEPTB;M{iuOFk4PCEQvF2= M3;USHNCVkeHUh?=
LB2241-RCC M2XZXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17y[mlEPTB;M{muPFIxPSEQvF2= NFjQR5VUSU6JRWK=
Detroit562 NVW5fm5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTRyLkGyOlgh|ryP MlGwV2FPT0WU
HN NYD1XlQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTRyLkG3PFIh|ryP NF22e21USU6JRWK=
HCT-15 NXWzTph3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jIfWlEPTB;NECuOVkxPyEQvF2= NHr2UnZUSU6JRWK=
C2BBe1 MnG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIK1O4lKSzVyPUSwMlkyPTdizszN M3fv[nNCVkeHUh?=
A498 NUPEd3BKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIK5fWhKSzVyPUSxMlMxOTVizszN NYfQOHJYW0GQR1XS
SK-MEL-24 M2XEfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDqTVBKSzVyPUSxMlQ4OjVizszN MlLaV2FPT0WU
OVCAR-5 NV\VWVBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTRzLke3Olch|ryP MmX2V2FPT0WU
NCI-H1792 NGjF[m9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{i3OmlEPTB;NEGuPVgzOSEQvF2= MmnlV2FPT0WU
KOSC-2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTR{LkK2PVkh|ryP Mm\IV2FPT0WU
Mo-T NX:zbHgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIO0TYJKSzVyPUSyMlg6PThizszN M1XtXHNCVkeHUh?=
CFPAC-1 MkG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonnTWM2OD12Mz60PVQ1KM7:TR?= M1LTfHNCVkeHUh?=
CAL-51 NUD0PW1DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LuOGlEPTB;NEOuOVYxPSEQvF2= M{ixd3NCVkeHUh?=
RH-18 NGHMXVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLwTWM2OD12Mz64NFUh|ryP NH;XUJlUSU6JRWK=
EC-GI-10 M3zF[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTR|LkizOFch|ryP NUHmdJN[W0GQR1XS
HSC-2 NGW1[ZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGK3ZoJKSzVyPUS0MlAxQSEQvF2= MmXUV2FPT0WU
ML-2 M1\X[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnKTWM2OD12NT6yOlIyKM7:TR?= Mk\6V2FPT0WU
KNS-81-FD MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTR3LkezOlUh|ryP NYm0R|J1W0GQR1XS
NB6 M{LwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTR4LkGxNUDPxE1? Mo\EV2FPT0WU
MCF7 Ml\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HPUWlEPTB;NE[uOVU{OyEQvF2= MnjjV2FPT0WU
P30-OHK NYfVemE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3O4UGlEPTB;NE[uPFEyPyEQvF2= MXrTRW5ITVJ?
BPH-1 NHvUOmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrCbZJKSzVyPUS2Mlk5ODVizszN M2GwSXNCVkeHUh?=
U251 NXHoOZJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LkOWlEPTB;NE[uPVk1KM7:TR?= NXjkTYlVW0GQR1XS
MKN1 M2n5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTR5LkWxN|ch|ryP Mo\mV2FPT0WU
A431 MnTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXSeZFLUUN3ME20O{45OzN6IN88US=> M3X1[XNCVkeHUh?=
C8166 NVu4[2lET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{D6ZWlEPTB;NEmuNlA{QSEQvF2= M3zUdnNCVkeHUh?=
HEL NXvKcplTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XFbGlEPTB;NEmuOFA3PCEQvF2= MkfqV2FPT0WU
RMG-I MkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTaNmtbUUN3ME20PU41PDR2IN88US=> MXPTRW5ITVJ?
CAL-72 MoHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTR7Lk[wO|Uh|ryP MoDuV2FPT0WU
SW962 NI\1SYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nqbmlEPTB;NEmuPVM{OiEQvF2= MmXIV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-c-kit / c-kit / p-AKT / AKT / p-ERK / ERK / p-STAT3 / STAT3 / p-STAT5 / STAT5 / p-S6K / S6K / p-S6 / S6; 

PubMed: 31205508     


Immunoblotting analysis of indicated proteins in c-KIT mediated signaling pathways of GIST-T1, GIST-882, GIST-48B, and GIST-5R cell lines.

PARP / cleaved PARP / caspase-3 / cleaved caspase-3; 

PubMed: 31205508     


Immunoblotting analysis of apoptosis-related proteins after axitinib treatment in human GIST cell lines. Imatinib and sunitinib were used as positive controls.

31205508
Immunofluorescence
alpha-tubulin; 

PubMed: 26474283     


Representative images of RCC cells treated as above described, and then immunostained with anti-α-tubulin antibody. Bar: 50 μM

26474283
Growth inhibition assay
Cell viability ; 

PubMed: 26474283     


A. A-498 and Caki-2 RCC cell lines were cultured up to 96 h with different doses of axitinib. Cell viability was determined by MTT assay. Data shown are expressed as mean ± SD of three separate experiments; *p < 0.01 vs vehicle-treated cells. B. RCC cell 䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ ⟸෕Ð㺣痖⟸෕€

26474283
In vivo Axitinib exhibits primary inhibition to orthotopically transplanted models such as M24met (melanoma), HCT-116 (colorectal cancer), and SN12C (renal cell carcinoma). [1] Axitinib delays the tumor growth with 11.4 days compared to the controls (p.o. 30 mg/kg) and decreases the Mean Vessels Density (MVD) to 21, compared to 49 in controls, in IGR-N91 flank xenografts. [2] Axitinib significantly inhibits growth and disrupts tumor microvasculature in BT474 breast cancer model at 10-100 mg/kg. [3] Axitinib has shown single-agent activity in variable tumors, including renal cell carcinoma, thyroid cancer, non-small cell lung cancer, and melanoma.

Protocol

Kinase Assay:

[1]

- Collapse

Cellular receptor kinase phosphorylation assay:

Porcine aorta endothelial (PAE) cells, which overexpress full-length VEGFR2, PDGFRβ, Kit, and NIH-3T3, which overexpress murine VEGFR2 (Flk-1) or PDGFRα, are generated. The 96-well plates are coated with 100 μL/well of 2.5 μg/mL anti-VEGFR2 antibody, 0.75 μg/mL anti-PDGFRβ antibody, 0.25 μg/mL anti-PDGFRα antibody, 0.5 μg/mL anti-KIT antibody, or 1.20 μg/mL anti-Flk-1 antibody to prepare ELISA capture plates. Then phosphorylation of RTK is measured by ELISA.
Cell Research:

[2]

- Collapse
  • Cell lines: HUVEC, SH-SY5Y, IGR-N91 and IGR-NB8 cells
  • Concentrations: 1 nM - 10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are seeded in a 96-well plate at a density of 5 × 104 and cultured for 24 hours. Axitinib is added to the cells at concentrations ranging from 1 nM to 10 μM. Cell viability is measured after 72 hours by MTS tetrazolium substrate and IC50 values are calculated.


    (Only for Reference)
Animal Research:

[3]

- Collapse
  • Animal Models: BT474 breast cancer cells are implanted subcutaneously into Immune-deficient female mice (Nu/nu; age 8-12 weeks).
  • Dosages: 10, 30 or 100 mg/kg
  • Administration: Oral daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 35 mg/mL warmed (90.56 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 386.47
Formula

C22H18N4OS

CAS No. 319460-85-0
Storage powder
in solvent
Synonyms AG 013736
Smiles CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)C=CC4=CC=CC=N4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04682587 Not yet recruiting Drug: Axitinib|Drug: Avelumab|Drug: Pembrolizumab Renal Cell Carcinoma Pfizer December 21 2020 --
NCT04669366 Not yet recruiting Drug: sunitinib|Drug: axitinib Kidney Neoplasms Pfizer December 15 2020 --
NCT04626128 Recruiting Drug: CLS-AX|Drug: Anti-VEGF Neovascular Age-related Macular Degeneration Clearside Biomedical Inc. December 15 2020 Phase 1|Phase 2
NCT04637204 Recruiting Drug: Cabozantinib|Drug: Axitinib Renal Cell Carcinoma Ipsen November 24 2020 --
NCT04555603 Active not recruiting Drug: Inlyta|Drug: Bavencio|Drug: Keytruda Renal Cell Carcinoma Pfizer September 15 2020 --
NCT04522323 Recruiting Biological: MEDI5752|Drug: Axitinib Advanced Renal Cell Carcinoma MedImmune LLC August 5 2020 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    We would like to store at -80℃ after it dissolved in CMC. Do you have any infomation about the suggested concentration in CMC?

  • Answer:

    Axitinib in 0.5% CMC at up to 30mg/ml is a suspension for oral gavage administration only. We don't suggest customer to freeze down the solution but to make fresh if possible. Customer can store it for 1-2 weeks at 4 degree for continuous use.

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Axitinib | Axitinib supplier | purchase Axitinib | Axitinib cost | Axitinib manufacturer | order Axitinib | Axitinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID